Solara Active Pharma Sciences Limited

SOLARA

INE624Z01016

Pharmaceuticals

Delayed NSE India S.E. Other stock markets 02:00:08 2024-06-21 EDT			5-day change	1st Jan Change
465 ^INR	+3.75%		+6.62%	+28.59%

06-12	Solara Active Pharma Sciences Closes INR4.50 Billion Rights Issue	MT
05-29	Solara Active Pharma Sciences Limited Re-Affirms Earnings Guidance for the Fiscal Year 2025	CI

Solara Active Pharma Sciences Limited Re-Affirms Earnings Guidance for the Fiscal Year 2025

May 29, 2024 at 06:30 am

Solara Active Pharma Sciences Limited re-affirmed earnings guidance for the fiscal year 2025. For the year, the company expects which is a revenue growth of approximately INR 15,000 million.

Latest news about Solara Active Pharma Sciences Limited

Solara Active Pharma Sciences Closes INR4.50 Billion Rights Issue	06-12	MT
Solara Active Pharma Sciences Limited Re-Affirms Earnings Guidance for the Fiscal Year 2025	05-29	CI
Transcript : Solara Active Pharma Sciences Limited, Q4 2024 Earnings Call, May 29, 2024	05-29
Solara Active Pharma Sciences Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2024	05-29	CI
Solara Active Pharma Gets Zero Observations from US FDA for Andhra Pradesh, India Unit	05-20	MT
USFDA Concludes Inspection At Solara's Visakhapatnam Facility with Zero 483 Inspectional Observations	05-20	CI
Solara Active Pharma to Raise 4.50 Billion Via Rights Issue	05-09	MT
Solara Active Pharma Sciences Limited Approves Appointment of Mohan Muthunarayanan as an Executive Director	04-08	CI
Solara Active Pharma Gets Board Nod to Sell 100% Stake in SeQuent Penems	03-25	MT
An undisclosed buyer agreed to acquire SeQuent Penems Private Limited from Solara Active Pharma Sciences Limited.	03-24	CI
Solara Active Pharma Sciences Appoints CFO	03-08	MT
Solara Active Pharma Sciences Limited Approves Appointment of Arun Kumar Baskaran as Chief Financial Officer	03-08	CI
Solara Active Pharma Sciences' Human Resource Chief Resigns	02-26	MT
Solara Active Pharma HR Chief Steps Down	02-26	MT
Solara Active Pharma Sciences Limited Announces Resignation of Pagadala Srinivasan as Chief Human Resource Officer	02-26	CI
Solara Active Pharma Sciences' CFO Resigns	02-14	MT
Solara Active Pharma Sciences Limited Announces the Resignation of P.V. Raghavendra Rao as Chief Financial Officer	02-14	CI
Transcript : Solara Active Pharma Sciences Limited, Q3 2024 Earnings Call, Feb 14, 2024	02-14
Solara Active Pharma Sciences Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	02-14	CI
Solara Active Pharma Sciences Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	02-14	CI
Solara Active to Sell Subsidiary's Land	11-14	MT
Solara Active Pharma Sciences Widens Consolidated Loss in Fiscal Q2	11-14	MT
Transcript : Solara Active Pharma Sciences Limited, Q2 2024 Earnings Call, Nov 14, 2023	11-14
Solara Active Pharma Sciences Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	11-14	CI
Fire Breaks Out at Solara Active Pharma's Puducherry, India Unit	11-05	MT

Chart Solara Active Pharma Sciences Limited

Duration

Period

Chart Solara Active Pharma Sciences Limited

More charts

Solara Active Pharma Sciences Limited is an India-based company offering diversified, commercial active pharmaceutical ingredients (APIs) and contract manufacturing services in over 70 countries. The Company operates through the API segment. Its commercial and research and development products include Albendazole, Aprepitant (Antiemetic), Artesunate, Brivaracetam (Antiepileptic), Bumetanide (Inj) (Loop Diuretic), Buspirone HCL (Anxiolytic), Cetirizine Dihydrochloride, Chlorpromazine Hydrochloride, Cinacalcet Hydrochloride (Calcimimetic Agent), Citicoline Sodium (Anticonvulsant), Colchicine (Antigout Agent), Colesevelam Hydrochloride, Cycloserine (Antitubercular), Ethacrynic Acid (Cardiovascular Agent), Hydralazine Hydrochloride (Anti-Hypertensive), Ibuprofen Sodium Dihydrate (Anti-inflammatory), Mesna (Antineoplastic Detoxifying Agent), Mirabegron (OAB Treatment), Pentoxifylline, and others. The Company works with pharmaceutical companies from North America, Europe, and Japan.

Sector

Pharmaceuticals

Calendar

2024-08-12 - Q1 2025 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Solara Active Pharma Sciences Limited

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

448.2 INR

Average target price

380.5 INR

Spread / Average Target

-15.10%

Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
SOLARA ACTIVE PHARMA SCIENCES LIMITED	+28.59%	257M
ELI LILLY AND COMPANY	+51.99%	798B
JOHNSON & JOHNSON	-5.72%	356B
MERCK & CO., INC.	+18.94%	328B
ABBVIE INC.	+11.07%	304B
ASTRAZENECA PLC	+16.96%	244B
ROCHE HOLDING AG	+2.25%	227B
NOVARTIS AG	+11.15%	216B
AMGEN INC.	+7.59%	166B
PFIZER, INC.	-3.65%	157B

Other Pharmaceuticals